Biotech

The GOAT of Women's Bobsleigh, Humphries Trusts Both Brands to Support Pain Relief, Sleep and Her Gut Health as She Prepares to Win More Gold in Beijing 2022

HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) ("HempFusion" or the "Company"), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce an exclusive partnership with two-time Olympic Gold Medalist and five-time World Champion Kaillie Humphries. HempFusion CBD and Probulin Probiotics will be Kaillie's exclusive sponsors in their respective categories through February's Olympic Games in Beijing 2022 where she is the front-runner for gold for Team USA in both the Two-woman Bobsleigh and the newly introduced Women's Monobob.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005336/en/

Two-time Olympic Gold Medalist in Bobsled, Kaillie Humphries, holds her five World Championship medals. (Photo: Business Wire)

Two-time Olympic Gold Medalist in Bobsled, Kaillie Humphries, holds her five World Championship medals. (Photo: Business Wire)

In February 2021, Kaillie extended her claim as the greatest women's bobsleigh athlete of all time by winning the Two-woman Bobsleigh as well as the Women's Monobob competition at the World Championships in Altenberg, Germany.

In 2014, Kaillie lobbied the International Bobsleigh and Skeleton Federation to introduce a Four-Person Bobsleigh competition including both men and women and became the first woman to pilot an all-woman team in a men's World Cup.

Emboldened by the possibility of change within the sport, Kaillie has become a champion for gender equality and is actively leading an international movement that resulted in the inclusion of Women's Monobob in the Olympic program beginning in Beijing 2022.

With the recent introduction of the Monobob competition to the 2021 World Championships, Kaillie has found a new focus on extending her dominance and growing legacy in the sport of bobsleigh and competing for Team USA with the goal of winning two Olympic gold medals.

Off the track, Kaillie has continued to push the boundaries of female strength and athleticism. In 2019, her relentless workouts on Instagram caught the attention of Sports Illustrated that named her #17 on the list of the Fittest 50 Women in Sports .

"I'm excited to join the HempFusion family of brands," said Humphries. "When you train as hard as I do, there's going to be some post workout pain, and I prefer to deal with it using natural products . I've done my due diligence, with a number of CBD brands, and I concluded that HempFusion is not only highly effective, but the CBD brand that I can trust to be free of THC and other contaminants."

"Kaillie Humphries is an exceptional champion, one of the greatest of all time, both on and off the track, and we couldn't be prouder that HempFusion and Probulin products have earned her trust," commented Ian deQueiroz, Chief of Brand Strategy for HempFusion Wellness Inc. "Her success, through strength and dedication, is inspiring and her advocacy for women's equality in sport empowers generations of women who follow."

"Probulin is another brand I know I can trust to be clean and effective," continued Humphries. "Gut health plays a big role in overall wellness and Probulin probiotic supplements give me the support I need."

"Partnering with a champion of Kallie's stature provides us with an incredible opportunity to educate millions of fans around the world about the wellness benefits of both HempFusion CBD and Probulin Probiotics," said Jason Mitchell, N.D., Chief Executive Officer of HempFusion Wellness Inc. "Our recent launch on Tmall is especially timely since her arrival in China, a country that loves sport, is highly anticipated. Billions of people will watch her go for more gold."

As the exclusive CBD and probiotic sponsor of Kaillie Humphries, HempFusion and Probulin look forward to delivering unique digital opportunities and marketing assets including branding on her apparel, social media campaigns, testimonials, personal appearances and more.

Kaillie joins Team HempFusion's roster of world class athletes including UFC Hall of Famer and ESPN analyst, Michael Bisping, freestyle snowboarding icon, Travis Rice, professional rallycross driver Steve Arpin and Loenbro Motorsports, UFC contender, Brian Ortega, numerous international professional and Olympic level BMX bikers, professional wingsuit flyer and one of " The 25 Most Adventurous Women of the Past 25 Years " by Men's Journal, Steph Davis, and many more.

HempFusion's family of brands are available through approximately 4,000 retail locations across all 50 states and select international locations and from HempFusion.com and Probulin.com .

Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .

Follow Kaillie Humphries on Instagram @KaillieHumphries and Twitter @BobsledKaillie .

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion's diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion's wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion's CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Ian deQueiroz
Chief of Brand Strategy, HempFusion Wellness Inc.
Email: MediaInquiries@HempFusion.com
Phone: 847-772-4195

News Provided by Business Wire via QuoteMedia

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2022, at 4:30 p.m. EDT.

Cardiol Therapeutics 2022 AGM

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

- By signing the Kigali Declaration, Gilead joins the global community committed to ending neglected tropical diseases by 2030 -

Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declaration is an important milestone for the World Health Organization's 2030 road map which includes global targets to prevent, control and in some cases eliminate 20 diseases and disease groups by 2030.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities

AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact Week of Possibilities is AbbVie's global, in-person volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering

NORTH CHICAGO, Ill. , June 27, 2022 /PRNewswire/ -- AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local communities around the world. From June 27 to July 1 , AbbVie employees will work with trusted community partners to complete hands-on projects, including renovating schools, playgrounds and community centers, to benefit local communities impacting tens of thousands of people.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

"As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry, including the equity capital markets, banking practices and financial transaction experience," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We are delighted to have him join our executive management team and will benefit from his leadership, strategic insights, and guidance as we advance HM43239 and luxeptinib through clinical development toward commercialization."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

CHMP Recommends Approval of Upadacitinib for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

  • CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ ® ) met the primary endpoint of ASAS40 response at week 14 versus placebo 1
  • Non-radiographic axial spondyloarthritis (nr-axSpA) is part of the axial spondyloarthritis (axSpA) spectrum and causes inflammation in the spine, leading to back pain and stiffness 2,3,4
  • The EC decision is expected in the third quarter of 2022

ABBVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) andor magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

"Patients with axSpA often experience delayed diagnosis and once they do receive a diagnosis, there are limited therapies available to help control disease symptoms, such as inflammation, back pain and stiffness," said Neil Gallagher , M.D., Ph.D., vice president, development, chief medical officer, AbbVie. "The CHMP's recommendation to approve upadacitinib for patients with nr-axSpA is an important milestone in providing a new treatment option to patients in need."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×